Welmoed Kirsten van Deen, MD

TitleAssistant Professor of Clinical Medicine
InstitutionUniversity of Southern California
AddressGNH 1937 Hospital Place
Off Campus
Los Angeles CA 90031
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    Leiden University, The Netherlands2011LUSTRA Travel Scholarship
    American Gastroenterological Association2015Digestive Disease Week Poster of Distinction Award

    Collapse Overview 
    Collapse Overview
    Dr. van Deen's major areas of research interest are value-based healthcare implementation and outcome and utilization measurement. She is currently a member of the International Consortium for Health Outcomes Measurement (ICHOM) IBD Standard Set Working Group.

    Dr. van Deen earned her medical degree from Leiden University Medical Center. She then returned to complete her PhD in Medicine a few years later.

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Vaughn DA, van Deen W, Kerr WT, Meyer TR, Bertozzi AL, Hommes DW, Cohen MS. Using insurance claims to predict and improve hospitalizations and biologics use in members with inflammatory bowel diseases. J Biomed Inform. 2018 May; 81:93-101. PMID: 29625187.
      View in: PubMed
    2. Kim AH, Roberts C, Feagan BG, Banerjee R, Bemelman W, Bodger K, Derieppe M, Dignass A, Driscoll R, Fitzpatrick R, Gaarentstroom-Lunt J, Higgins PD, Kotze PG, Meissner J, O'Connor M, Ran ZH, Siegel CA, Terry H, van Deen W, van der Woude CJ, Weaver A, Yang SK, Sands BE, Vermeire S, Travis SP. Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease-an International, Cross-disciplinary Consensus. J Crohns Colitis. 2018 Mar 28; 12(4):408-418. PMID: 29216349.
      View in: PubMed
    3. van Deen W, Spiro A, Burak Ozbay A, Skup M, Centeno A, Duran NE, Lacey PN, Jatulis D, Esrailian E, van Oijen MG, Hommes DW. The impact of value-based healthcare for inflammatory bowel diseases on healthcare utilization: a pilot study. Eur J Gastroenterol Hepatol. 2017 Mar; 29(3):331-337. PMID: 27926663.
      View in: PubMed
    4. van Deen W, Nguyen D, Duran NE, Kane E, van Oijen MG, Hommes DW. Value redefined for inflammatory bowel disease patients: a choice-based conjoint analysis of patients' preferences. Qual Life Res. 2017 02; 26(2):455-465. PMID: 27582169.
      View in: PubMed
    5. Van Deen WK, van der Meulen-de Jong AE, Parekh NK, Kane E, Zand A, DiNicola CA, Hall L, Inserra EK, Choi JM, Ha CY, Esrailian E, van Oijen MG, Hommes DW. Development and Validation of an Inflammatory Bowel Diseases Monitoring Index for Use With Mobile Health Technologies. Clin Gastroenterol Hepatol. 2016 Dec; 14(12):1742-1750.e7. PMID: 26598228.
      View in: PubMed
    6. Oikonomopoulos A, van Deen W, Manansala AR, Lacey PN, Tomakili TA, Ziman A, Hommes DW. Optimization of human mesenchymal stem cell manufacturing: the effects of animal/xeno-free media. Sci Rep. 2015 Nov 13; 5:16570. PMID: 26564250; PMCID: PMC4643287.
    7. Zand A, van Deen W, Inserra EK, Hall L, Kane E, Centeno A, Choi JM, Ha CY, Esrailian E, D'Haens GR, Hommes DW. Presenteeism in Inflammatory Bowel Diseases: A Hidden Problem with Significant Economic Impact. Inflamm Bowel Dis. 2015 Jul; 21(7):1623-30. PMID: 26070004.
      View in: PubMed
    8. Polytarchou C, Hommes DW, Palumbo T, Hatziapostolou M, Koutsioumpa M, Koukos G, van der Meulen-de Jong AE, Oikonomopoulos A, van Deen W, Vorvis C, Serebrennikova OB, Birli E, Choi J, Chang L, Anton PA, Tsichlis PN, Pothoulakis C, Verspaget HW, Iliopoulos D. MicroRNA214 Is Associated With Progression of Ulcerative Colitis, and Inhibition Reduces Development of Colitis and Colitis-Associated Cancer in Mice. Gastroenterology. 2015 Oct; 149(4):981-92.e11. PMID: 26055138; PMCID: PMC4584179 [Available on 10/01/16].
    9. van Deen W, Esrailian E, Hommes DW. Value-based health care for inflammatory bowel diseases. J Crohns Colitis. 2015 May; 9(5):421-7. PMID: 25687204.
      View in: PubMed
    10. van Deen W, van Oijen MG, Myers KD, Centeno A, Howard W, Choi JM, Roth BE, McLaughlin EM, Hollander D, Wong-Swanson B, Sack J, Ong MK, Ha CY, Esrailian E, Hommes DW. A nationwide 2010-2012 analysis of U.S. health care utilization in inflammatory bowel diseases. Inflamm Bowel Dis. 2014 Oct; 20(10):1747-53. PMID: 25137415.
      View in: PubMed
    11. Oikonomopoulos A, van Deen W, Hommes DW. Anti-TNF antibodies in inflammatory bowel disease: do we finally know how it works? Curr Drug Targets. 2013 Nov; 14(12):1421-32. PMID: 23627866.
      View in: PubMed
    12. van Deen W, Hommes DW. IBD: Antibodies to anti-TNF therapy--consequences for IBD management. Nat Rev Gastroenterol Hepatol. 2013 Aug; 10(8):446-8. PMID: 23817324.
      View in: PubMed
    13. van Deen W, Oikonomopoulos A, Hommes DW. Stem cell therapy in inflammatory bowel disease: which, when and how? Curr Opin Gastroenterol. 2013 Jul; 29(4):384-90. PMID: 23666365.
      View in: PubMed
    14. van Deen W, Hommes DW. Mucosal schwann cell hamartoma in ulcerative colitis: diagnosis and clinical relevance. Gastroenterol Hepatol (N Y). 2013 Mar; 9(3):185-6. PMID: 23961271; PMCID: PMC3745210.
    15. Molendijk I, Duijvestein M, van der Meulen-de Jong AE, van Deen W, Swets M, Hommes DW, Verspaget HW. Immunomodulatory effects of mesenchymal stromal cells in Crohn's disease. J Allergy (Cairo). 2012; 2012:187408. PMID: 23049573; PMCID: PMC3459229.